Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
FH-3421 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
FH-3421: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
AP-L1898 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
AP-L1898: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
JBI-802 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
JBI-802: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
HPV 16 E7/HSP70 fused DNA vaccine(The Johns Hopkins University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
HPV 16 E7/HSP70 fused DNA vaccine(The Johns Hopkins University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
INB-03 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
INB-03: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Immune Cell Extracorporeal Therapy(Artcline GmbH) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Immune Cell Extracorporeal Therapy(Artcline GmbH): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
TJ-062 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
TJ-062: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
ALN-6400 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
ALN-6400: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
INNA-051 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
INNA-051: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
AHB-171 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
AHB-171: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
AAV9-GAN gene therapy(Pfizer Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
AAV9-GAN gene therapy(Pfizer Inc.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals.
8 min read
Cyproheptadine Hydrochloride/Prazosin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Cyproheptadine Hydrochloride/Prazosin Hydrochloride: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP.